WO2005037071A3 - Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy - Google Patents

Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy Download PDF

Info

Publication number
WO2005037071A3
WO2005037071A3 PCT/US2004/033815 US2004033815W WO2005037071A3 WO 2005037071 A3 WO2005037071 A3 WO 2005037071A3 US 2004033815 W US2004033815 W US 2004033815W WO 2005037071 A3 WO2005037071 A3 WO 2005037071A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
rtk
tyrosine kinase
receptor tyrosine
diagnosis
Prior art date
Application number
PCT/US2004/033815
Other languages
French (fr)
Other versions
WO2005037071A2 (en
Inventor
Ali Mukherjee
Mengxiang Tang
Harprit S Pannu
Po-Ying Chan-Hui
Sharat Singh
Original Assignee
Monogram Biosciences Inc
Ali Mukherjee
Mengxiang Tang
Harprit S Pannu
Po-Ying Chan-Hui
Sharat Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monogram Biosciences Inc, Ali Mukherjee, Mengxiang Tang, Harprit S Pannu, Po-Ying Chan-Hui, Sharat Singh filed Critical Monogram Biosciences Inc
Priority to EP04795034A priority Critical patent/EP1681983A4/en
Publication of WO2005037071A2 publication Critical patent/WO2005037071A2/en
Publication of WO2005037071A3 publication Critical patent/WO2005037071A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Abstract

The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.
PCT/US2004/033815 2003-10-14 2004-10-13 Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy WO2005037071A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04795034A EP1681983A4 (en) 2003-10-14 2004-10-13 Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US51091003P 2003-10-14 2003-10-14
US60/510,910 2003-10-14
US56635204P 2004-04-28 2004-04-28
US60/566,352 2004-04-28
US57181604P 2004-05-17 2004-05-17
US60/571,816 2004-05-17
US57725604P 2004-06-03 2004-06-03
US60/577,256 2004-06-03

Publications (2)

Publication Number Publication Date
WO2005037071A2 WO2005037071A2 (en) 2005-04-28
WO2005037071A3 true WO2005037071A3 (en) 2007-06-07

Family

ID=34468485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033815 WO2005037071A2 (en) 2003-10-14 2004-10-13 Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy

Country Status (3)

Country Link
US (2) US7402399B2 (en)
EP (1) EP1681983A4 (en)
WO (1) WO2005037071A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
WO2003067210A2 (en) 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
US7774143B2 (en) * 2002-04-25 2010-08-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
WO2004092353A2 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Surface receptor complexes as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
NZ545873A (en) 2003-08-11 2009-05-31 Monogram Biosciences Inc Detecting and profiling molecular complexes
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
EP1842147A2 (en) * 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Method for modeling cell signaling systems by means of bayesian networks
KR101387456B1 (en) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1946120A2 (en) * 2005-10-18 2008-07-23 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
BRPI0717416A2 (en) 2006-09-21 2013-11-12 Prometheus Lab Inc METHOD FOR PERFORMING A HIGH PRODUCTIVITY COMPLEX IMMUNOASON, AND
WO2011008990A1 (en) 2009-07-15 2011-01-20 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
RU2519647C2 (en) * 2007-07-13 2014-06-20 Нестек С.А. Selection of medications for lung cancer therapy by means of antibody-based matrices
CA2706763C (en) 2007-11-27 2013-07-30 Laboratory Corporation Of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
US10416162B2 (en) * 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
CA2923248A1 (en) 2008-02-25 2009-09-03 Nestec S.A. Methods for detecting truncated receptors
GB2474146B (en) * 2008-04-29 2013-04-10 Nodality Inc Methods of determining the health status of an individual
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8399206B2 (en) * 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
ES2535723T3 (en) 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Methods for determining the patient's response by measuring Her-3
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
US20100332417A1 (en) * 2009-06-02 2010-12-30 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
US20110010782A1 (en) * 2009-07-09 2011-01-13 Microsoft Corporation Adapting parasites to combat disease
AU2010306862B2 (en) 2009-10-13 2015-08-27 Nanostring Technologies, Inc. Protein detection via nanoreporters
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
CA2835284C (en) 2011-05-19 2020-08-25 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
WO2013033623A1 (en) * 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
EP3224621B1 (en) 2014-11-25 2019-06-12 Ventana Medical Systems, Inc. Proximity assays using chemical ligation and hapten transfer
SG10202107055SA (en) 2015-07-17 2021-08-30 Nanostring Technologies Inc Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
SG10202107053QA (en) 2015-07-17 2021-08-30 Nanostring Technologies Inc Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
EP3403095B1 (en) 2016-03-15 2019-08-07 Laboratory Corporation of America Holdings Methods of assessing protein interactions between cells
CN109789204A (en) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 Method based on the selection patients with mastocarcinoma medicinal treatment of HER2 and HER3 access hypotype
AU2017361521B2 (en) 2016-11-21 2020-08-27 Nanostring Technologies, Inc. Chemical compositions and methods of using same
WO2019157445A1 (en) 2018-02-12 2019-08-15 Nanostring Technologies, Inc. Biomolecular probes and methods of detecting gene and protein expression
SG11202011274YA (en) 2018-05-14 2020-12-30 Nanostring Technologies Inc Chemical compositions and methods of using same
WO2020080892A1 (en) * 2018-10-19 2020-04-23 주식회사 프로티나 Drug targeting heterodimer of her2 and her3 and method for screening same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650750A (en) * 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
WO2004087887A2 (en) * 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
US7105308B2 (en) * 2002-07-25 2006-09-12 Monogram Biosciences, Inc. Detecting receptor oligomerization

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4772550A (en) 1986-02-10 1988-09-20 Miles Inc. Heterogeneous specific binding assay employing an aggregatable binding reagent
GB8607101D0 (en) 1986-03-21 1986-04-30 Serono Diagnostics Ltd Immunoassay
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4891324A (en) 1987-01-07 1990-01-02 Syntex (U.S.A.) Inc. Particle with luminescer for assays
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6037134A (en) * 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
US5545527A (en) 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US6025128A (en) 1994-09-29 2000-02-15 The University Of Tulsa Prediction of prostate cancer progression by analysis of selected predictive parameters
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
AU1837495A (en) 1994-10-13 1996-05-06 Horus Therapeutics, Inc. Computer assisted methods for diagnosing diseases
US5578253A (en) 1994-11-23 1996-11-26 Lumigen, Inc. Chemiluminescent dialkyl-substituted 1,2-dioxetane compounds, methods of synthesis and use
SE504798C2 (en) 1995-06-16 1997-04-28 Ulf Landegren Immunoassay and test kits with two reagents that can be cross-linked if adsorbed to the analyte
US20040010300A1 (en) * 1996-02-13 2004-01-15 Leonardo Masotti Device and method for biological tissue stimulation by high intensity laser therapy
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6001573A (en) 1996-06-14 1999-12-14 Packard Bioscience B.V. Use of porphyrins as a universal label
WO1998001548A1 (en) 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
GB9705949D0 (en) 1997-03-21 1997-05-07 Electrophoretics International Diagnosis of tumours and other abnormalities of body cells
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
EP1078265A1 (en) 1998-02-18 2001-02-28 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6248546B1 (en) 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6370478B1 (en) 1998-12-28 2002-04-09 Rosetta Inpharmatics, Inc. Methods for drug interaction prediction using biological response profiles
US6110109A (en) 1999-03-26 2000-08-29 Biosignia, Inc. System and method for predicting disease onset
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6383740B2 (en) 1999-07-30 2002-05-07 Bioergonomics, Inc. Methods for simultaneously detecting both members of a binding pair
ES2330301T3 (en) 1999-08-27 2009-12-09 Genentech, Inc. DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES.
WO2001053539A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US9335328B2 (en) 2000-02-03 2016-05-10 Instant Medical Diagnostics, Llc Method and apparatus for signal transduction pathway profiling
UA73967C2 (en) 2000-02-14 2005-10-17 First Opinion Corp Structure-based automatic processing for diagnostics (variants)
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
AUPQ886100A0 (en) 2000-07-19 2000-08-10 Biotron Limited Diagnostic test
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
EP1328656A4 (en) 2000-09-29 2005-09-14 Univ Johns Hopkins Med Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
US6666820B1 (en) 2000-11-28 2003-12-23 Michael D. Poole Mathematical therapeutic outcomes model for predicting clinical efficacy therapies
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
CN1559006A (en) 2001-05-21 2004-12-29 埃克来拉生物科学公司 Methods and compositions for analyzing proteins
AU2002365517A1 (en) 2001-11-26 2003-06-10 Hybrigenics Protein-protein interactions involving transforming growth factor beta signalling
WO2003068808A1 (en) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Novel protein complexes and uses therefor
CA2477953A1 (en) 2002-03-01 2003-09-12 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US7774143B2 (en) 2002-04-25 2010-08-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states
US20040018528A1 (en) 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
EP1514213A2 (en) 2002-05-20 2005-03-16 Rosetta Inpharmactis LLC. Computer systems and methods for subdividing a complex disease into component diseases
US7402397B2 (en) * 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
WO2003102154A2 (en) 2002-05-29 2003-12-11 Discoverx, Inc. Improved receptor detection
AU2003251597A1 (en) 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
PT1585966E (en) 2002-07-15 2012-02-20 Hoffmann La Roche Treatment of cancer with the anti-erbb2 antibody rhumab 2c4
US7348184B2 (en) 2002-07-24 2008-03-25 Bio-Rad Laboratories, Inc. Protein interaction difference mapping
DK1388734T3 (en) 2002-08-01 2004-05-03 Mtm Lab Ag Method for solution-based diagnosis
JP2006515742A (en) 2002-08-27 2006-06-08 ブリストル−マイヤーズ　スクイブ　カンパニー Identification of polynucleotides to predict the activity of compounds that interact and / or modulate the protein tyrosine kinase and / or protein tyrosine kinase pathway in breast cancer cells
US20040103001A1 (en) 2002-11-26 2004-05-27 Mazar Scott Thomas System and method for automatic diagnosis of patient health

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650750A (en) * 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US7105308B2 (en) * 2002-07-25 2006-09-12 Monogram Biosciences, Inc. Detecting receptor oligomerization
WO2004087887A2 (en) * 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Also Published As

Publication number Publication date
US20090011440A1 (en) 2009-01-08
EP1681983A2 (en) 2006-07-26
WO2005037071A2 (en) 2005-04-28
US20050131006A1 (en) 2005-06-16
US7402399B2 (en) 2008-07-22
EP1681983A4 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
WO2005037071A3 (en) Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
WO2006044748A3 (en) RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2004087887A3 (en) Intracellular complexes as biomarkers
WO2003035846A3 (en) Structure of tall-1 and its cognate receptor
WO2003085095A3 (en) Novel expressed genes
WO2003029421A3 (en) Regulated breast cancer genes
WO2002016412A3 (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CN105229164A (en) The SRM of instruction cancer therapy measures
WO2004096985A3 (en) Methods for assessing biologic diversity
EP2053403A3 (en) Affinity fishing for ligands and proteins receptors
WO2003051302A3 (en) Methods and compositions for treatment of central nervous system disorders
WO2007027867A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO1999007738A3 (en) Human orphan receptor ntr-1
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2005045058A3 (en) Detecting human anti-therapeutic antibodies
WO2005001061A3 (en) Polynucleotides encoding novel adiponectin receptor variants
WO2007041502A3 (en) Methods for determining responsiveness to cancer therapy
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
WO2003094848A3 (en) Nucleic acid-associated proteins
WO2003087338A3 (en) Her-2 receptor tyrosine kinase molecules and uses thereof
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2006084018A3 (en) Methods for determining responsiveness to cancer therapy
WO2004012673A3 (en) Methods and reagents relating to inflammation and apoptosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004795034

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004795034

Country of ref document: EP